Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-20 of 20 for your search:
Drug:
arsenic trioxide
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LAP-R2007
, NCT00504764
2.
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
30052004
, NCT00196768
3.
Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
UHW-AML16
, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
4.
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
IAPLSG2004
, BT/PR4460/Med/14/531/2003, NCT00517712
5.
Acute Promyelocytic Leukemia 2006 (APL)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
P050604
, NCT00378365
6.
Phase III Randomized Study of Arsenic Trioxide and Tretinoin Versus Combination Chemotherapy Comprising Tretinoin, Idarubicin, Mitoxantrone Hydrochloride, Methotrexate, and Mercaptopurine for Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
GIMEMA-DSL-APL0406
, EUDRACT-2006-006188-22, APL0406, EU-20725, NCT00482833
7.
Phase III Randomized Study of Induction and Consolidation Combination Chemotherapy With or Without Gemtuzumab Ozogamicin Followed By Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate Versus Observation in Patients With Previously Untreated Low- or Intermediate-Risk Acute Promyelocytic Leukemia
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0521
, S0521, NCT00492856
8.
Phase III Study of Risk-Adapted Induction Chemotherapy, Risk-Adapted Consolidation Combination Chemotherapy Including Arsenic Trioxide, and Maintenance Combination Chemotherapy in Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
COG-AAML0631
, COG-AAML0631, AAML0631, NCT00866918
9.
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
00008662
, 7365, NCT00590603
10.
All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab and Theophylline
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2006-0706
, NCT00413166
11.
Phase II Study of Induction and Consolidation Therapy Comprising Tretinoin, Arsenic Trioxide, and Gemtuzumab Ozogamicin Followed by Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate in Patients With Previously Untreated, High-Risk Acute Promyelocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0535
, S0535, NCT00551460
12.
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04-267
, PI-Initiated, NCT00582400
13.
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
00011792
, 7667A, NCT00621023
14.
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
9L-07-12
, NCT00670150
15.
Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
AISSM02A
, EudracT Number 2005-001321-28, NCT00803530
16.
Phase I Study of Arsenic Trioxide and Radiotherapy in Pediatric Patients With Newly Diagnosed Anaplastic Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Intrinsic Pontine Glioma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
JHOC-J0423
, JHOC-04041906, NCT00095771
17.
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UCI 06-08
, NCT00571116
18.
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-0916
, NCT00671697
19.
Phase I Study of Radiotherapy, Arsenic Trioxide, and Temozolomide in Patients With Newly Diagnosed Grade III or IV Glioma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07058
, 07058, CEPHALON-CHNMC-07058, NCT00720564
20.
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Phase:
Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NU 08H9
, NCT00985530
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
